P/E ratio for Maravai LifeSciences (MRVI)
P/E ratio as of April 2024 (TTM): 12.9
According to Maravai LifeSciences 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 12.9414. At the end of 2022 the company had a P/E ratio of 8.57.
P/E ratio history for Maravai LifeSciences from 2020 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 8.57 | -68.1% |
| 2021 | 26.9 | 24.77% |
| 2020 | 21.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Organovo ONVO | -0.5000 | -103.86% | 🇺🇸 USA |
 Orchard Therapeutics
ORTX | -2.69 | -120.81% | 🇬🇧 UK |
 Novavax NVAX | -0.5661 | -104.37% | 🇺🇸 USA |
 Novocure
NVCR | -6.36 | -149.15% | Jersey |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.